ZYDUS LIFESCIENCES: REGULATORY APPROVAL UPDATE

ZYDUSLIFE

• Received approval from China’s NMPA for Venlafaxine Extended-Release Capsules (75 mg & 150 mg). • This marks Zydus’ first-ever approval from the NMPA in China. • The product is indicated for treatment of Major Depressive Disorder and Anxiety Disorders. • The approval paves the way for Zydus’ entry into the Chinese CNS (Central Nervous System) therapeutics market.